



NET

IMPACT

Thrivership & Research Education Program












**Friday, June 26, 2026
3-7 p.m. ET**

Marriott Columbus OSU
3100 Olentangy River Rd.
Columbus, OH 43202



TABLE OF CONTENTS

Scroll or click on the text or logos below to navigate to sections of the booklet. To return to the Table of Contents, click the round, red TOC button at the end of each section. For optimal interactive performance, view this document in "read" mode.

-  **Welcome** 2
-  **Agenda** 3
-  **Fast Facts About Neuroendocrine Cancer** 4
-  **About NETRF** 5
-  **Get to Know Our Speakers** 7
-  **NET Knowledge Center** 10
-  **NETWise** 11
-  **Know Your NETs** 12
-  **Clinical Trials** 13
-  **Breakthroughs Today, Cures Tomorrow** 15
-  **A Word of Thanks** 28

WELCOME

Welcome to NET Impact, NETRF's Thrivership and Research Patient Education Program. We are excited to be with you in Columbus.

Our focus today is two-fold — what's new in research and treatment, plus how to thrive and live well with neuroendocrine cancer. Thank you to our physician co-chairs, Drs. Jordan Cloyd and Bhavana Kondra, for their participation and guidance. We thank all our speakers for sharing their expertise with you.

We hope you will increase your knowledge about neuroendocrine cancer today and gain some strategies to manage the challenges that accompany a neuroendocrine cancer diagnosis. The conference is also an opportunity to meet fellow patients and caregivers and network with others who can understand your experience.

NETRF sincerely thanks our sponsors, Boehringer Ingelheim, Camurus, Crinetics, Curium, Exelixis, ITM, Lantheus, Novartis and RayzeBio, who help make this conference possible, and we extend our gratitude to NANETS for their collaboration.

Above all, know that you are not alone if you have neuroendocrine cancer. NETRF is here as a resource today and every day. We welcome your feedback about this conference and how we can best meet your educational needs. Thank you for your time and interest!



Elyse Gellerman, MHS
*Chief Executive Officer,
Neuroendocrine Tumor Research Foundation*

Note to Attendees

This patient and caregiver education conference is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information found here with their oncologist, physician, or appropriate qualified health professional. Attending this conference does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient's oncologist, physician, or appropriate qualified health professional.

NET

Thrivership & Research Education Program

IMPACT

June 26, 2026 | 3-7 p.m. ET

Marriott Columbus OSU

3100 Olentangy River Rd., Columbus, OH 43202

Conference Co-Chairs:

Jordan Cloyd, MD – The Ohio State University

Bhavana Konda, MD, MPH – The Ohio State University

AGENDA

- 3:00 p.m. Thrivership Meet and Greet**
Refreshments will be provided.
- 4:20 p.m. Welcome and Program Introduction**
Elyse Gellerman, MHS – Chief Executive Officer, NETRF
- 4:30 p.m. What Makes Neuroendocrine Cancer Different**
Dan Halperin, MD – Winship Cancer Institute at Emory University
- 4:45 p.m. What's New in Treatments for Neuroendocrine Cancer?**
Jordan Cloyd, MD – The Ohio State University
Bhavana Konda, MD, MPH – The Ohio State University
- 5:05 p.m. What's New in Clinical Trials?**
Chandrikha Chandrasekharan, MD – MD Anderson Cancer Center
- 5:25 p.m. Managing Symptoms that Impact Your Quality of Life**
Dan Halperin, MD – Winship Cancer Institute at Emory University
- 5:45 p.m. The Future of Basic and Translational Research**
Anna Greene, PhD – Chief Scientific Officer, NETRF
- 6:05 p.m. NET Thrivership: Mental Health and Managing Stress**
Jessica Thomas, LCSW – Director of Patient Education, NETRF
- 6:25 p.m. NET IMPACT Program Q&A Panel**
Bhavana Konda, MD, MPH; Jordan Cloyd, MD;
Chandrikha Chandrasekharan, MD; Anna Greene, PhD;
Dan Halperin, MD
- 7:05 p.m. Program Closure and Evaluation**
Elyse Gellerman, MHS – Chief Executive Officer, NETRF

PROGRAM SPONSORS



CATERING SPONSORED BY





Fast Facts About Neuroendocrine Cancer

- Neuroendocrine cancer is an uncommon cancer yet the incidence has been increasing in recent decades. This is attributed in part to improvements in diagnostic techniques and greater awareness.
- More than **12,000 people** in the U.S. are diagnosed with a neuroendocrine cancer each year.
- The average length of time from first symptoms to diagnosis is **4.3 years**.¹
- The average number of health care visits made before a neuroendocrine cancer diagnosis is **11.8 visits**.¹
- Up to **58% of patients** had metastases at diagnosis.

¹ Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43-53.

ABOUT THE NEUROENDOCRINE TUMOR RESEARCH FOUNDATION (NETRF)

The Neuroendocrine Tumor Research Foundation is the largest global funder of neuroendocrine cancer research, investing \$43 million in landmark research since 2005. NETRF’s mission is to drive transformational discoveries in the study of neuroendocrine cancer. We are leading the fight to bring life-changing treatments to families and to find a cure.



NETRF:

- Invests boldly in the most promising scientific projects worldwide
- Funds and nurtures the most brilliant scientists who bring their original thinking and determined spirit to their work
- Offers hope to patients and families
- Shapes the future of neuroendocrine cancer care to save lives

NETRF’s impact on the field of neuroendocrine cancer research has been profound. Thanks to NETRF-funded discoveries and the efforts of the neuroendocrine cancer medical community, the therapeutic landscape of neuroendocrine cancer management looks entirely different now than it did in 2005, when NETRF began. Such advances are not random. They are the direct result of many years of NETRF-funded research.


\$43M in NETRF funded breakthrough science

22 clinical trials fueled by NETRF-supported research


156
research projects funded


76
institutions in 17 countries


8
new therapies since NETRF began

 **View our 2025 Annual Report to see recent major milestones and how we’re accelerating discoveries.**

EDUCATING AND EMPOWERING PATIENTS

NETRF is dedicated to the thousands of patients, families, and caregivers affected by neuroendocrine cancer. We provide expert educational resources to help you understand your diagnosis, make informed health care decisions, and thrive.


Our resources include:



NET Knowledge Center

NET Knowledge Center

A comprehensive online resource for information, engagement, and community building



Neuroendocrine Cancer Guide

A hands-on reference for the tests, treatments, and management of neuroendocrine cancer



NETWise Podcast series

Insights and perspectives on living with neuroendocrine cancer



NETRF YouTube library

Videos about diagnosis, treatment, research, and living with neuroendocrine cancer



Patient and caregiver education conferences

In-person and virtual events for knowledge- and community-building



Searchable databases

Includes neuroendocrine cancer doctors and multidisciplinary treatment programs


GET TO KNOW OUR SPEAKERS



Chandrikha Chandrasekharan, MBBS, MD

MD Anderson Cancer Center

Dr. Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-lead the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care.



Jordan Cloyd, MD

The Ohio State University

Dr. Jordan Cloyd is currently an Associate Professor of Surgery and the Ward Professor of Surgical Oncology at The Ohio State University Wexner Medical Center where he is the section lead of HPB/GI surgical oncology. He completed his general surgery residency at Stanford University and fellowship in complex general surgical oncology at MD Anderson Cancer Center. His clinical practice focuses on the management of hepatopancreatobiliary cancers whereas his research focuses on patient-centered outcomes of multimodality therapy and the role of supportive care in oncology. He is program director of the hepatopancreatobiliary surgery fellowship at The Ohio State and the Editor-In-Chief of the Journal of Gastrointestinal Cancer.



Elyse Gellerman, MHS

Chief Executive Officer, NETRF

Elyse has been Chief Executive Officer of the Neuroendocrine Tumor Research Foundation since November 2017. As CEO, she has built a team that has vastly expanded NETRF’s global reach in research funding and patient education. Prior to NETRF, Elyse was a Regional Vice President for Sarah Cannon, the oncology service line for Hospital Corporation of America (HCA). Elyse spent more than 20 years in hospital service line development, operations consulting, and marketing. She has served on the national board at Susan B. Komen, and been a member of other health-related nonprofit boards. In 2011, Elyse was recognized by the Obama Administration as a Champion for Change in the fight against breast cancer. Elyse graduated from Cornell University and has a master’s degree in healthcare systems from the University of Denver.



GET TO KNOW OUR SPEAKERS, cont.



Anna Greene, PhD

Chief Scientific Officer, NETRF

As NETRF's Chief Scientific Officer, Dr. Greene leads the foundation's research programs, oversees the annual grant cycle, supervises post-award processes, organizes the annual research symposium, and reports research impact and outcomes to the community. She is motivated to help advance neuroendocrine cancer research to understand the disease better and ultimately identify better treatments and cures. She earned a BS in chemistry from Berry College and a PhD in chemistry from Dartmouth College.



Daniel M. Halperin, MD

Winship Cancer Institute at Emory University

A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in the treatment of neuroendocrine cancer. Dr. Halperin is part of the gastrointestinal oncology team at Winship Cancer Institute at Emory University. He is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Halperin is Chair, NETRF Board of Scientific Advisors and also serves on the NANETS Board of Directors.

He received his medical degree from Weill Cornell Medical College in New York City, New York. Dr. Halperin completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.



Bhavana Konda, MD, MPH

The Ohio State University

Dr. Bhavana Konda is a Professor of Internal Medicine in the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center, where she serves as Section Chief and Disease-Specific Research Group Leader for Neuroendocrine and Endocrine Medical Oncology. She completed her Internal Medicine residency at the University of Miami West Palm Beach Campus in Florida, followed by a fellowship in Hematology and Oncology at the Albert Einstein College of Medicine/Montefiore Medical Center in New York. Dr. Konda specializes in the management of neuroendocrine and endocrine cancers and is committed to improving outcomes for patients with these malignancies through innovative clinical research, multidisciplinary collaboration, and compassionate, patient-centered care.

GET TO KNOW OUR SPEAKERS, cont.



Jessica Thomas, LCSW

Director of Patient Education, NETRF

Jessica Thomas, LCSW, is a clinical social worker with nearly 20 years of experience supporting patients and caregivers navigating neurology, oncology, and chronic illness. With a career rooted in mental health care for those facing complex medical conditions, Jessica is deeply committed to helping individuals and families identify and embrace what matters most to them while living with chronic, progressive, or terminal illness. She is passionate about fostering community, advancing patient-centered care, supporting research, and improving the overall patient experience and outcomes.





BECOME INFORMED, ENGAGED AND CONNECTED IN YOUR NET JOURNEY

Current and accurate patient education and information is vital to helping you live well with neuroendocrine cancer. We know that finding credible information and education can be challenging and difficult to navigate.

NETRF's NET Knowledge Center is a comprehensive resource organized to direct you to the information you need to be engaged in your neuroendocrine cancer journey while connecting you to a community of resources.

INFORMATION

Learn more about neuroendocrine cancers

A diagnosis of a neuroendocrine tumor often comes with many questions and concerns. These resources explain the various types of neuroendocrine cancers, diagnostic tests, and risks so you and your family can better understand your condition.

ENGAGEMENT

Take the next step regarding your diagnosis

With many different kinds of neuroendocrine cancers, it's important to find the best possible care and treatment. These resources explore finding specialists, treatments, and how best to care for yourself.

COMMUNITY

Connect with more people and resources about neuroendocrine cancer

When it comes to neuroendocrine tumors, it takes a community. Explore the many ways you can access the latest information on treatments and research progress, and what's happening in the neuroendocrine cancer community.



Visit the NET Knowledge Center at netrf.org/for-patients/ or scan this QR code.



NETwise

A Podcast About Neuroendocrine Cancer

Being diagnosed with neuroendocrine cancer, an uncommon disease, can feel isolating and overwhelming. The NETwise podcast is here to help patients and caregivers navigate the world of neuroendocrine tumors and carcinomas.


Listen as the NET Research Foundation (NETRF) speaks with experts and patients who will help you to understand diagnosis, treatment, thrivership and everything in between. NETwise is for everyone, from newly diagnosed patients to longtime survivors, as well as caregivers and family members.

This is your guide to learning, listening, knowing, and being NETwise.

Check out these trending episodes for more on what you have heard during KNOW YOUR NETs:

- [Care for the Neuroendocrine Carcinoma Caregiver](#)
- [Understanding Neuroendocrine Carcinoma](#)
- [Managing the Financial Burden of Neuroendocrine Cancer](#)
- [Radiopharmaceutical Treatment: FAQs and Insights](#)
- [How Could AI Change Neuroendocrine Cancer](#)
- [Finding Happiness While Living With Neuroendocrine Cancer](#)
- [Managing Symptoms of NENs](#)

Subscribe [here](#) and find our entire NETwise library. Listen to NETwise wherever you get your podcasts.



Neuroendocrine Tumor
Research Foundation
100 Hancock Street, Third Floor
Quincy, MA 02171
(617) 946-1780 | netrf.org



NEUROENDOCRINE TUMOR
RESEARCH FOUNDATION



From our 2025 Know Your NETs Conference

NETs and NECs 101

Presented by Kimberly Perez, MD, Dana Farber Cancer Institute



Know Your NETs Presentation:



The 2025 Know Your NETs Preconference Video: NETs and NECs 101



Kimberly Perez, MD
Dana-Farber Cancer Institute

Watch NETs and
NECs 101



This introductory session is designed to help patients, caregivers, and advocates understand the basics of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Dr. Perez breaks down the essential concepts, terminology, and differences between NETs and NECs in a clear and approachable way — equipping you with the knowledge to get the most out of the full conference. Topics include:

- What are NETs and NECs?
- Key differences in biology and behavior
- How NETs and NECs are diagnosed and staged
- An overview of treatment options and care teams

Whether you're newly diagnosed or looking for a refresher, this video ensures you're prepared to take charge of your care.




**Register for the Know Your NETs
virtual conference on July 18, 2026.**

CLINICAL TRIALS

Clinical trials can provide patients with innovative treatments and are the final step in a long process that begins with research in a lab. Before any new treatment is used in people in clinical trials, researchers work for many years in the lab to understand its effects by testing it first on cells or in animals. They then work to determine the best dose for treatment, the side effects the drug may cause, and how the effectiveness of the drug compares to current treatments. It can take 10-15 years to develop a new drug to the point of a first clinical trial. Our online NET Trial Finder can connect you to clinical trials in your area.

NET Trial Finder



The screenshot shows the top navigation bar with the NET logo, "NEUROENDOCRINE TUMOR RESEARCH FOUNDATION", and "powered by ancora.ai". It includes links for "LEARN", "LOGIN", and "SIGN UP". The main content area features the heading "MATCH & CONNECT" and "Finding clinical trials made simple". Below this is a search bar with a dropdown menu set to "Neuroendocrine tumors/cancer", a text input field for "Enter city and country", and a "Find Trials" button. Underneath, there is a section "Explore trials by category" with a button for "Radiopharmaceuticals". An illustration of a stethoscope, a computer monitor with a checklist, and a pill bottle is also present.



FIND A CLINICAL TRIAL

There are many clinical trials for neuroendocrine cancer. Scan this QR code to access the NET Trial Finder, or visit netrf.org/for-patients/trial-finder/

Find it early. Treat it better. Cure it faster.



“I truly believe in the mission and the great work that NETRF is doing year in and year out. I want to be part of the solution — and I want to see a future where we find a cure.”

— Steve Kaufer,
NETRF Board Member,
Co-Founder, TripAdvisor,
Co-Founder, Give Freely

For over 20 years, NETRF has led the global charge to transform neuroendocrine cancer treatment.

Now, we are launching our most ambitious campaign yet — a **\$25 million** effort to accelerate the bold science that will deliver new therapies and, ultimately, cures.

With your support, NETRF is advancing progress in three urgent and high-impact areas:

- **Early Detection** — So patients are diagnosed sooner, when treatment is more effective
- **New Therapeutic Development** — To expand treatment options and improve survival
- **Personalized Treatments** — To ensure every patient receives the right care at the right time

**Researchers are ready. Bold ideas are waiting.
They just need our support.**

Your Impact So Far:



156

research projects
funded



76

institutions in
17 countries



70%

increase in research
proposals since 2023

\$43 million

invested in breakthrough science

22

clinical trials fueled by
NETRF-supported research



Early Detection



CURES



This Is the Moment to Create Tomorrow's Cures

The discoveries happening today — in labs, clinics, and collaborative research teams — are transforming what's possible for patients and families facing neuroendocrine cancer.

But breakthroughs need you.

Your gift drives progress by:

- Funding life-changing research led by the world's leading scientists
- Powering innovations like CAR T-cell therapy from lab to lives
- Equipping patients and caregivers with trusted education and resources

Let's unlock breakthroughs together.


Make your gift today! Visit netrf.org/breakthroughs or scan the QR code to learn more.



**Breakthroughs Today, Cures Tomorrow.
Our future starts now.**



Robust Researcher Pipeline



Innovative Treatments




Precision Medicine



TOC

THANK YOU TO OUR PROGRAM SPONSORS





**Boehringer
Ingelheim**

camurus®

Developing a new treatment option for your patients with **neuroendocrine tumors (NET)**



Camurus continues its commitment to empowering patients and improving the lives of those affected by severe, chronic, and rare diseases. Scan to learn more >



©2025 Camurus Inc. All rights reserved. US-NPR-2500011 05/25

Learn About the SORENTO Trial


An ongoing, randomized, active-controlled Phase 3 trial assessing the efficacy and safety of an investigational octreotide subcutaneous depot prefilled pen (CAM2029) versus octreotide LAR or lanreotide ATG in patients with GEP-NETs (NCT05050942).¹

Primary objective:

SORENTO™

To demonstrate the **superiority of treatment** with CAM2029, compared with treatment with octreotide LAR or lanreotide ATG, on **progression-free survival (PFS)** in patients with unresectable/metastatic and well-differentiated GEP-NET

Approximately **300 patients** randomized to receive CAM2029 Q2W or treatment with the investigator's choice of comparator




After 194 patients have confirmed progressive disease, the **primary outcomes (PFS)** will be assessed, and patients will continue to be followed up for survival for up to 2 years

*Histologically confirmed, advanced, well-differentiated NET of GEP/presumed GEP origin, with ≥1 measurable somatostatin receptor-positive lesion according to RECIST 1.1 and <6 months or no prior consecutive treatment with long-acting SRLs; [†]Patients in both treatment groups may receive octreotide immediate release (≤600 µg/day) as a rescue medication in line with local practice; [‡]Patients in either treatment group will continue with the same treatment in the OLR period until progressive disease is confirmed (defined as per RECIST 1.1, per BIRC), death, unacceptable toxicity precluding further treatments, loss of follow-up, or treatment discontinuation; [§]Defined as per RECIST 1.1; ^{||}After confirmation of progressive disease in the OLR treatment period, patients in both treatment groups may enter the open-label extension period and switch to CAM2029 20 mg every week; [¶]Primary PFS analysis will be performed after 194 patients have confirmed progressive disease, and if the primary endpoint is met, the comparator group may switch to CAM2029.

ATG, Autogel; BIRC, blinded independent review committee; GEP-NET, gastroenteropancreatic neuroendocrine tumor; LAR, long-acting repeatable; OLR, open-label randomized; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; SRL, somatostatin receptor ligand.

1. Singh S, et al. *Trials*. (2024) 25:58.






A world leader in nuclear medicine, Curium is driven to advance patient care

100% Focus
on radiopharmaceuticals

100% Committed
to partnering with hospitals, providers, advocacy groups, and patients to improve the cancer care experience



EXELIXIS[®]



RAYTHERITY[®]
(lutetium Lu 177 edotreotide)
injection for intravenous use



COMING SOON

Scan the QR code to learn more



© 2026 ITM USA, Inc. All rights reserved. ITM[®] and RAYTHERITY[®]
are registered trademarks of ITM Isotope Technologies Munich SE.
M-US-RAY-0009 | April 2026





Innovation that makes an impact

Learn more about our
passion to **Find, Fight
and Follow[®]** disease
to deliver better patient
outcomes.



Visit us:
Lantheus.com



LANTHEUS[®]

 [@Lantheus](https://www.linkedin.com/company/Lantheus)

Let's reimagine medicine, together



End-to-end solutions to help accelerate patient access

For treatment centers and referring providers



Insurance Support

- Benefits investigation
- Prior authorization requirements
- Appeals support
- Billing, coding, and reimbursement education (for treatment centers only)



Financial Support

- Eligible patients may pay as little as \$0 per dose. Subject to terms and conditions. Limitations apply*
- Enrollment is required to determine eligibility and participation



Accessing Treatment

- Access to ROME ordering platform
- Help with product ordering
- Real-time delivery tracking
- Treatment center locator
- Additional offerings available for referring sites



Patient Education

Live 1-on-1 support is available for patients starting treatment. Our Patient Navigators can help answer the most common treatment questions.

Our team is available to assist you every step of the way

Patient Navigators assist treatment centers and referring offices with access, reimbursement, and affordability services. They can also provide 1-on-1 patient education.

Phone: 1-844-638-7222

Customer Support Associates assist treatment centers with product ordering and delivery.

Phone: 1-844-367-3222

Your local Access and Reimbursement Field Representative is available to assist you with all our support services.

ROME, radiopharmaceutical order management environment.

Thank you to
our catering sponsor

RayzeBio[®]
A Bristol Myers Squibb Company

**Discovering and
developing
radiopharmaceuticals
for patients living
with cancer**



A WORD OF THANKS!

Thank you for taking part in NETRF's NET Impact conference. We hope you found the sessions informative and valuable.

If you have any questions about NETRF, our research and resources, and how we can best support you on your journey with neuroendocrine cancer, please contact us at info@netrf.org.

We are grateful to our generous partners and friends like you. Thanks to your support, NETRF can host educational conferences and advance research, opening new doors to neuroendocrine cancer discoveries.

NETRF greatly appreciates the generosity of the following sponsors who made this educational program possible. Thank you!

Our sponsors



Catering sponsored by



Visit our YOUTUBE channel for patient education videos.



Connect with us and other patients, caregivers, and family members online:

